Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
Morton JI, Marquina C, Shaw JE et, al.
Diabetologia. Pub. online 21 Nov 2022.
Leggi